Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $192.50 short put and a strike $187.50 long put offers a potential 22.25% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $192.50 by expiration. The full premium credit of $0.91 would be kept by the premium seller. The risk of $4.09 would be incurred if the stock dropped below the $187.50 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 31.39 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Tue, 24 Sep 2019 20:00:00 +0000
THOUSAND OAKS, Calif., Sept. 24, 2019 /PRNewswire/ — Amgen (AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with high-risk, B-cell acute lymphoblastic leukemia (ALL) at first relapse. Enrollment was terminated early due to encouraging efficacy in the BLINCYTO arm and was based on a recommendation from the Independent Data Monitoring Committee (DMC).
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent
Mon, 23 Sep 2019 16:08:04 +0000
Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.
Amgen Looks Attractive After Its Recent Pullback
Sun, 22 Sep 2019 17:33:00 +0000
Amgen's AMG 510 phase 1 results helped change the narrative around the stock, but that was just the beginning.
Amgen (AMGN) Gains As Market Dips: What You Should Know
Fri, 20 Sep 2019 21:50:09 +0000
In the latest trading session, Amgen (AMGN) closed at $196.94, marking a +0.66% move from the previous day.
5 Safe Bets for a Rocky Market
Fri, 20 Sep 2019 20:29:08 +0000
Here are 5 companies with proven track records.
Also on Market Tamer…
Follow Us on Facebook